The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 

Nirmatrelvir-ritonavir, sold by Pfizer under the name Paxlovid, is commonly prescribed to treat COVID-19. When treating some heart patients, however, physicians may want to consider an alternative approach.

Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes. 

Researchers examined data from more than 1,800 CLTI patients, comparing bypass surgery with minimally invasive treatment options such as angioplasty and stenting.

The new guidance document was designed to help cardiologists and other clinicians deliver the best care possible when treating ASCVD patients who present with additional conditions that need to be considered.